Immutep (IMMP) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 29, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Oct 24, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMMP SEC filings page.
Immutep Limited (IMMP) reported $6.8M in revenue for fiscal year 2025, up 29.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Immutep Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Immutep Limited, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Immutep Limited had 1.46B shares outstanding at the end of fiscal year 2025, against 1.45B in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Immutep Limited scores 48/100 among other emerging companies.
Immutep Limited spent $32.7M on research and development in fiscal year 2025, which was 100.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Immutep Limited scores 99/100 among other emerging companies.
Immutep Limited reported revenue of $6.8M in fiscal year 2025, against $5.2M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Immutep Limited scores 75/100 among other emerging companies.
Immutep Limited's operations used $40.8M of cash in fiscal year 2025, against $23.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Immutep Limited scores 24/100 among other emerging companies.
Not available for Immutep Limited, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Immutep Limited passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) passes.
Immutep Limited reported a net loss of $40.4M while operations used $40.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Immutep Limited generated $6.8M in revenue in fiscal year 2025. This represents an increase of 29.7% from the prior year.
Immutep Limited reported a net loss of $40.4M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Immutep Limited earned -$0.03 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Immutep Limited recorded an outflow of $40.8M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Immutep Limited held $44.3M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Immutep Limited's ROE was -42.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 20.2 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Immutep Limited invested $32.7M in research and development in fiscal year 2025. This represents an increase of 55.7% from the prior year.
Immutep Limited invested $30K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.2% from the prior year.
Not reported for fiscal year 2025.
IMMP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M+29.7% | $5.2M+51.1% | $3.5M-25.7% | $4.7M+56.9% | $3.0M-73.8% | $11.4M+116.7% | $5.2M-3.5% | $5.4M+67.9% | $3.2M+114.9% | $1.5M |
| R&D Expenses | $32.7M+55.7% | $21.0M+9.5% | $19.2M+9.7% | $17.5M+94.2% | $9.0M-16.1% | $10.7M+11.2% | $9.7M+30.6% | $7.4M+28.0% | $5.8M+10.1% | $5.2M |
| Interest Expense | $24K+19.3% | $20K+50.3% | $14K-78.7% | $64K+766.6% | $7K+2.2% | $7Kn/m | $0 | N/A | N/A | $6K |
| Income Tax | $0n/m | $0n/m | $0-100.0% | $23-5.1% | $25-3.0% | $26n/m | $0-100.0% | $1Kn/m | -$566Kn/m | -$878K |
| Net Income | -$40.4Mn/m | -$28.5Mn/m | -$26.6Mn/m | -$22.2Mn/m | -$22.4Mn/m | -$9.3Mn/m | -$12.9Mn/m | -$9.4Mn/m | -$7.2Mn/m | -$46.1M |
| EPS (Basic) | -$0.03n/m | -$0.02n/m | -$0.03n/m | -$0.03n/m | -$0.04n/m | -$0.02 | -$3.71n/m | -$3.43 | -$0.31n/m | -$2.07 |
| EPS (Diluted) | -$0.03n/m | -$0.02n/m | -$0.03n/m | -$0.03n/m | -$0.04n/m | -$0.02 | -$3.71n/m | -$3.43 | -$0.31n/m | -$2.07 |
| Diluted Shares (Avg) | 1.46B+21.2% | 1.20B+34.6% | 892M+5.1% | 849M+42.7% | 595M+44.1% | 413M | 347M+26.1% | 275M | 2.37B+6.4% | 2.23B |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, Operating Income, EBITDA.
IMMP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $103.2M-23.3% | $134.6M+37.0% | $98.2M+39.3% | $70.5M+14.7% | $61.5M+91.4% | $32.1M+13.0% | $28.4M-18.3% | $34.8M+29.6% | $26.8M-15.1% | $31.6M |
| Current Assets | $98.0M-23.3% | $127.8M+42.1% | $89.9M+43.4% | $62.7M+22.3% | $51.3M+138.8% | $21.5M+30.1% | $16.5M-22.1% | $21.2M+73.4% | $12.2M | N/A |
| Cash & Equivalents | $44.3M-59.0% | $108.0M+31.4% | $82.2M+48.9% | $55.2M+21.6% | $45.4M+150.3% | $18.1M+56.2% | $11.6M-33.1% | $17.4M+84.9% | $9.4M-39.5% | $15.5M |
| Accounts Receivable | $6.5M+32.2% | $4.9M-7.4% | $5.3M-8.4% | $5.8M+25.9% | $4.6M+102.2% | $2.3M-37.6% | $3.6M+43.4% | $2.5M+50.8% | $1.7M | N/A |
| Goodwill | $4.7M-14.0% | $5.5M-13.0% | $6.3M-13.2% | $7.3M-24.3% | $9.6M-8.1% | $10.5M-11.8% | $11.9M-12.4% | $13.6M-7.1% | $14.6M-5.8% | $15.5M |
| Total Liabilities | $8.8M+9.0% | $8.1M+10.0% | $7.3M+30.9% | $5.6M-14.9% | $6.6M-28.4% | $9.2M-19.0% | $11.3M+13.5% | $10.0M+54.1% | $6.5M+20.3% | $5.4M |
| Current Liabilities | $8.4M+19.8% | $7.0M+7.5% | $6.5M+47.0% | $4.4M+10.6% | $4.0M+72.6% | $2.3M-37.6% | $3.7M+30.3% | $2.9M+41.1% | $2.0M | N/A |
| Non-Current Liabilities | $387K-63.1% | $1.0M+30.4% | $805K-30.5% | $1.2M-54.8% | $2.6M-62.6% | $6.8M-10.0% | $7.6M+6.8% | $7.1M+59.9% | $4.5M | N/A |
| Total Equity | $94.4M-25.4% | $126.5M+39.2% | $90.9M+40.0% | $65.0M+18.3% | $54.9M+139.3% | $23.0M+34.3% | $17.1M-31.1% | $24.8M+21.8% | $20.4M-22.4% | $26.2M |
| Retained Earnings | -$291.9Mn/m | -$255.5Mn/m | -$226.5Mn/m | -$208.8Mn/m | -$205.9Mn/m | -$190.0Mn/m | -$183.8Mn/m | -$181.0Mn/m | -$178.0M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Long-Term Debt.
IMMP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$40.8Mn/m | -$23.3Mn/m | -$23.6Mn/m | -$20.9Mn/m | -$13.2Mn/m | -$7.5Mn/m | -$10.7Mn/m | -$5.8Mn/m | -$6.5Mn/m | -$8.4M |
| Capital Expenditures | $30K+54.2% | $20K-64.6% | $55K+248.4% | $16K+35.3% | $12K-12.3% | $13K-54.1% | $29K+230.0% | $9K+72.5% | $5K-74.7% | $20K |
| Free Cash Flow | -$40.8Mn/m | -$23.3Mn/m | -$23.6Mn/m | -$20.9Mn/m | -$13.2Mn/m | -$7.5Mn/m | -$10.7Mn/m | -$5.8Mn/m | -$6.5Mn/m | -$8.4M |
| Investing Cash Flow | -$25.3Mn/m | -$14.0Mn/m | -$55Kn/m | -$16Kn/m | -$12Kn/m | -$13Kn/m | -$29Kn/m | -$9Kn/m | -$5K-106.7% | $76K |
| Financing Cash Flow | -$345K-100.5% | $63.6M+25.5% | $50.7M+45.8% | $34.7M-12.0% | $39.5M+179.8% | $14.1M+151.3% | $5.6M-58.8% | $13.6Mn/m | -$7K-100.0% | $19.1M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
IMMP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | -594.6% | -545.0% | -767.2% | -476.6% | -753.6% | -81.6% | -244.9% | -173.3% | -221.9% | -3056.6% |
| Return on Equity | -42.8%-20.2pp | -22.5%+6.7pp | -29.2%+5.0pp | -34.2%+6.6pp | -40.8%-0.4pp | -40.5%+34.8pp | -75.2%-37.2pp | -38.0%-2.7pp | -35.3%+140.3pp | -175.6% |
| Return on Assets | -39.1%-17.9pp | -21.2%+5.9pp | -27.1%+4.5pp | -31.5%+4.9pp | -36.4%-7.6pp | -28.9%+16.4pp | -45.3%-18.1pp | -27.1%-0.3pp | -26.8%+118.9pp | -145.7% |
| Current Ratio | 11.69-6.6x | 18.25+4.4x | 13.81-0.3x | 14.16+1.3x | 12.81+3.6x | 9.26+4.8x | 4.44-3.0x | 7.43+1.4x | 6.05 | N/A |
| Liabilities-to-Equity | 0.090.0x | 0.060.0x | 0.080.0x | 0.090.0x | 0.12-0.3x | 0.40-0.3x | 0.66+0.3x | 0.40+0.1x | 0.32+0.1x | 0.20 |
| Asset Turnover | 0.070.0x | 0.040.0x | 0.040.0x | 0.070.0x | 0.05-0.3x | 0.35+0.2x | 0.180.0x | 0.160.0x | 0.12+0.1x | 0.05 |
| FCF Margin | -601.0% | -444.6% | -681.5% | -447.7% | -444.9% | -65.8% | -204.7% | -105.9% | -201.7% | -558.8% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Immutep Limited IMMP | FY2025 | $6.8M | -$40.4M | N/A | $24.5M | 62/100 |
| Candel Therapeutics, Inc. CADL | FY2025 | N/A | -$38.2M | N/A | $661.9M | — |
| Editas Medicine, Inc. EDIT | FY2025 | $40.5M | -$160.1M | N/A | $450.0M | 44/100 |
| AC Immune SA ACIU | FY2025 | $4.5M | -$88.8M | N/A | $235.6M | 51/100 |
| Fennec Pharmaceuticals Inc. FENC | FY2025 | $44.6M | -$9.7M | -21.8% | $384.0M | 52/100 |
| Humacyte, Inc. HUMA | FY2025 | $2.0M | -$40.8M | N/A | $130.6M | 41/100 |
Where Immutep Limited Ranks
Frequently Asked Questions
What is Immutep Limited's annual revenue?
Immutep Limited (IMMP) reported $6.8M in total revenue for fiscal year 2025. This represents a 29.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Immutep Limited's revenue growing?
Immutep Limited (IMMP) revenue grew by 29.7% year-over-year, from $5.2M to $6.8M in fiscal year 2025.
Is Immutep Limited profitable?
No, Immutep Limited (IMMP) reported a net loss of $40.4M in fiscal year 2025.
What is Immutep Limited's return on equity (ROE)?
Immutep Limited (IMMP) has a return on equity of -42.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Immutep Limited's free cash flow?
Immutep Limited (IMMP) recorded an outflow of $40.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Immutep Limited's operating cash flow?
Immutep Limited (IMMP) recorded an outflow of $40.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Immutep Limited's total assets?
Immutep Limited (IMMP) had $103.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Immutep Limited's capital expenditures?
Immutep Limited (IMMP) invested $30K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Immutep Limited spend on research and development?
Immutep Limited (IMMP) invested $32.7M in research and development during fiscal year 2025.
What is Immutep Limited's current ratio?
Immutep Limited (IMMP) had a current ratio of 11.69 as of fiscal year 2025, which is generally considered healthy.
What is Immutep Limited's liabilities-to-equity ratio?
Immutep Limited (IMMP) had a liabilities-to-equity ratio of 0.09 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Immutep Limited's return on assets (ROA)?
Immutep Limited (IMMP) had a return on assets of -39.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Immutep Limited's P/E ratio?
Immutep Limited (IMMP) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $24.5M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immutep Limited's price-to-sales ratio?
Immutep Limited (IMMP) trades at 3.6x sales, its market capitalization divided by $6.8M revenue, FY2025. The market capitalization is $24.5M as of Oct 29, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Immutep Limited's Piotroski F-Score?
Immutep Limited (IMMP) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Immutep Limited's earnings high quality?
Immutep Limited (IMMP) reported a net loss of $40.4M while operations used $40.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Immutep Limited?
Immutep Limited (IMMP) scores 62 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Immutep Limited it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.